Aura Biosciences (AURA) Net Cash Flow (2020 - 2026)

Aura Biosciences' Net Cash Flow history runs 7 years deep, the most recent figure standing at $25.3 million for Q1 2026.

• Quarterly Net Cash Flow rose 286.1% year-over-year to $25.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $46.8 million (up 291.05% YoY) and the FY2025 annual result came in at $28.0 million, up 398.75% from the prior year.
• Net Cash Flow was $25.3 million for Q1 2026 at Aura Biosciences, up from $12.2 million in the prior quarter.
• Across five years, Net Cash Flow topped out at $69.1 million in Q2 2025 and bottomed at -$83.1 million in Q1 2023.
• A 5-year average of -$3.7 million and a median of $6.3 million in 2024 frame the typical range for Net Cash Flow.
• Peak annual rise in Net Cash Flow reached 1721.18% in 2025, while the deepest fall reached 1181.06% in 2025.
• Aura Biosciences' Net Cash Flow stood at $60.3 million in 2022, then tumbled by 124.08% to -$14.5 million in 2023, then surged by 143.29% to $6.3 million in 2024, then surged by 93.51% to $12.2 million in 2025, then soared by 108.03% to $25.3 million in 2026.
• Business Quant data shows AURA's Net Cash Flow at $25.3 million in Q1 2026, $12.2 million in Q4 2025, and -$59.8 million in Q3 2025.